IP Verse

Igg1 Fc Mutants With Ablated Effector Functions - EP3692065

The patent EP3692065 was granted to Cilag on Feb 16, 2022. The application was originally filed on Oct 1, 2018 under application number EP18778497A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3692065

CILAG
Application Number
EP18778497A
Filing Date
Oct 1, 2018
Status
Granted And Under Opposition
Jan 14, 2022
Grant Date
Feb 16, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ZWICKER SCHNAPPAUF & PARTNERNov 16, 2022HOPFNERADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2008022759
DESCRIPTIONWO2012143524
DESCRIPTIONWO2013135588
DESCRIPTIONWO2014044758
DESCRIPTIONWO2014108483
DESCRIPTIONWO2014170063
DESCRIPTIONWO2015141862
DESCRIPTIONWO9211018
INTERNATIONAL-SEARCH-REPORTWO2012130831
INTERNATIONAL-SEARCH-REPORTWO2014170063
INTERNATIONAL-SEARCH-REPORTWO2016050721
INTERNATIONAL-SEARCH-REPORTWO2016081643
OPPOSITIONUS2017198041
OPPOSITIONWO2019068632

Non-Patent Literature (NPL) Citations (67) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410-
DESCRIPTION- ALTSCHUL et al., Methods in Enzymology, (19960000), vol. 266, pages 460 - 480-
DESCRIPTION- ALTSCHUL et al., Nucl. Acids Res., (19930000), vol. 25, pages 3389 - 3402-
DESCRIPTION- ALTSCHUL et al., Nucleic Acids Res., (19970000), vol. 25, pages 3389 - 3402-
DESCRIPTION- ALTSCHUL SF et al., Nucleic Acids Res., (19970000), vol. 25, pages 3389 - 3402-
DESCRIPTION- ASHKENAZI A; CHAMOW SM, Curr Opin Immunol., (19970000), vol. 9, no. 2, pages 195 - 200-
DESCRIPTION- BERTSCHINGER et al., Protein Eng Des Sel, (20070000), vol. 20, no. 2, pages 57 - 68-
DESCRIPTION- BOLT S et al., Eur J Immunol, (19930000), vol. 23, no. 2, pages 403 - 411-
DESCRIPTION- BRACK et al., Mol Cancer Ther, (20140000), vol. 13, no. 8, pages 2030 - 9-
DESCRIPTION- BRACK et al., Mol Cancer Ther, (20140000), vol. 13, pages 2030 - 2039-
DESCRIPTION- BRUHNS P et al., Blood, (20090000), vol. 113, no. 16, pages 3716 - 3725-
DESCRIPTION- CANFIELD SM; SL MORRISON, J Exp Med, (19910000), vol. 173, no. 6, pages 1483 - 1491-
DESCRIPTION- CIBELLI et al., Science, (19980000), vol. 280, pages 1256 - 1258-
DESCRIPTION- "Current Methods in Sequence Comparison and Analysis", Macromolecule Sequencing and Synthesis, Selected Methods and Applications, Alan R. Liss, Inc., (19880000), pages 127 - 149-
DESCRIPTION- DEVEREUX et al., Nucl. Acid Res., (19840000), vol. 12, pages 387 - 395-
DESCRIPTION- EVANS; KAUFMAN, Nature, (19810000), vol. 292, pages 154 - 156-
DESCRIPTION- GEBAUER; SKERRA, Curr Opinion in Chemical Biology, (20090000), vol. 13, pages 245 - 255-
DESCRIPTION- GILLILAND et al., PNAS, (19800000), vol. 77, pages 4539 - 4543-
DESCRIPTION- GONG Q et al., J Immunol, (20050000), vol. 174, no. 2, pages 817 - 826-
DESCRIPTION- GONG, Q et al., J Immunol, (20050000), vol. 174, no. 2, pages 817 - 826-
DESCRIPTION- GORDON et al., Proc Natl Acad Sci U S A., (19800000), vol. 77, pages 7380 - 4-
DESCRIPTION- GRABULOVSKI et al., JBC, (20070000), vol. 282, pages 3196 - 3204-
DESCRIPTION- HEROLD KC et al., Diabetes, (20050000), vol. 54, no. 6, pages 1763 - 1769-
DESCRIPTION- IDUSOGIE EE et al., J Immunol, (20000000), vol. 164, no. 8, pages 4178 - 4184-
DESCRIPTION- JEFFERIS R; M-P LEFRANC, mAbs, (20090000), vol. 1, pages 1 - 7-
DESCRIPTION- JONES, Nature, (19860000), vol. 321, pages 522 - 525-
DESCRIPTION- KARIN et al., Proc. Natl. Acad. Sci. U.S.A., (19930000), vol. 90, pages 5873 - 5787-
DESCRIPTION- KELTON W et al., Chem Biol, (20140000), vol. 21, pages 1603 - 1609-
DESCRIPTION- KISHORE et al., Immunopharmacology, (20000000), vol. 49, pages 159 - 170-
DESCRIPTION- KUO TT; VG AVESON, MAbs, (20110000), vol. 3, no. 5, pages 422 - 430-
DESCRIPTION- MARTIN WL et al., Mol Cell, (20010000), vol. 7, no. 4, pages 867 - 877-
DESCRIPTION- MOORE GL et al., Mabs, (20100000), vol. 2, no. 2, pages 181 - 189-
DESCRIPTION- NEEDLEMAN; WUNSCH, J. Mol. Biol., (19700000), vol. 48, page 443-
DESCRIPTION- NIMMCRJAHN; RAVETCH, Nature Reviews Immunology, (20080000), vol. 8, pages 34 - 47-
DESCRIPTION- NOSE M; H WIGZELL, Proc Natl Acad Sci U S A, (19830000), vol. 80, no. 21, pages 6632 - 6636-
DESCRIPTION- PARREN PW et al., J Immunol, (19920000), vol. 148, no. 3, pages 695 - 701-
DESCRIPTION- PEARSON; LIPMAN, Proc. Nat. Acad. Sci. U.S.A., (19880000), vol. 85, page 2444-
DESCRIPTION- REDMAN JM et al., Mol Immunol, (20150000), vol. 67, no. 2, pages 28 - 45-
DESCRIPTION- ROOPENIAN, Nature Reviews Immunology, (20070000), vol. 7, pages 715 - 725-
DESCRIPTION- RYAN et al., Science, (19970000), vol. 278, pages 873 - 876-
DESCRIPTION- SAZINSKY SL et al., Proc Natl Acad Sci USA, (20080000), vol. 105, pages 20167 - 20172-
DESCRIPTION- SCHLOTHAUER T et al., Protein Eng Des Sel, (20160000), vol. 29, pages 457 - 466-
DESCRIPTION- SHIELDS et al., J Biol Chem, (20010000), vol. 276, no. 9, pages 6591 - 6604-
DESCRIPTION- SHIELDS RL et al., J Biol Chem, (20010000), vol. 276, no. 9, pages 6591 - 6604-
DESCRIPTION- SHIELDS RL et al., J Biol Chem, (20010000), vol. 276, pages 6591 - 6604-
DESCRIPTION- SILACCI et al., mAbs, (20160000), vol. 8, no. 1, pages 141 - 149-
DESCRIPTION- SJOBERG et al., Trends Immunol., (20090000), vol. 30, no. 2, pages 83 - 90-
DESCRIPTION- SMITH; WATERMAN, Adv. Appl. Math., (19810000), vol. 2, page 482-
DESCRIPTION- STAVENHAGEN JB et al., Cancer Res, (20070000), vol. 67, pages 8882 - 8890-
DESCRIPTION- STEWART RH et al., Journal of ImmunoTherapv of Cancer, (20140000), vol. 2, no. 29-
DESCRIPTION- STEWART RH et al., Journal of ImmunoTherapy of Cancer, (20140000), vol. 2, no. 29-
DESCRIPTION- STROHL WR, Curr Opin Biotechnol, (20090000), vol. 20, no. 6, pages 685 - 691-
DESCRIPTION- TAO MH; SL MORRISON, J Immunol, (19890000), vol. 143, no. 8, pages 2595 - 2601-
DESCRIPTION- TSURUSHITA; VASQUEZ, Humanization of Monoclonal Antibodies, Molecular Biology of B Cells, Elsevier Science (USA, (20040000), pages 533 - 545-
DESCRIPTION- VAFA, O.; G. L. GILLILAND; R. J. BREZSKI; B. STRAKE; T. WILKINSON; E. R. LACY; B. SCALLON; A. TEPLYAKOV; T. J. MALIA; W. R. STROHL, Methods, (20140000), vol. 65, no. 1, pages 114 - 126-
DESCRIPTION- VERHOEYEN et al., Science, (19880000), vol. 239, pages 1534 - 1536-
DESCRIPTION- WHITE AL et al., J Immunol, (20110000), vol. 187, no. 4, pages 1754 - 1763-
DESCRIPTION- WILSON NS et al., Cancer Cell, (20110000), vol. 19, no. 1, pages 101 - 113-
DESCRIPTION- WOOF JM; DR BURTON, Nat Rev Immunol, (20040000), vol. 4, no. 2, pages 89 - 99-
DESCRIPTION- XU D et al., Cell Immunol, (20000000), vol. 200, no. 1, pages 16 - 26-
INTERNATIONAL-SEARCH-REPORT- MEGAN LO ET AL, "Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice", JOURNAL OF BIOLOGICAL CHEMISTRY, (20170111), vol. 292, no. 9, doi:10.1074/jbc.M116.767749, ISSN 0021-9258, pages 3900 - 3908, XP055428854 [A] 1-20 * abstract * * figure 1 * * page 3902 - page 3904 *
OPPOSITION- "DRUG: Drozitumab", URL: https://www.genome.ip/entry/D09888-
OPPOSITION- GONG QIAN,ET AL, "Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy.", The Journal of Immunology, Williams & Wilkins Co., US, US , (20050115), vol. 174, no. 2, ISSN 0022-1767, pages 817 - 826, XP002382101-
OPPOSITION- IDUSOGIE ESOHE E, ET AL., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc", The Journal of Immunology, Williams & Wilkins Co., US, US , (20000101), vol. 164, ISSN 0022-1767, pages 4178 - 4184, XP002965858-
OPPOSITION- Nicholas S. Wilson, Becky Yang, Annie Yang, Stefanie Loeser, Scot Marsters, David Lawrence, Yun Li, Robert Pitti, Klara Totpal, Sharon Yee, "An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells", Cancer cell, Cell Press, (20110118), vol. 19, no. 1, doi:10.1016/j.ccr.2010.11.012, ISSN 15356108, pages 101 - 113, XP055101108
OPPOSITION- SHIELDS R L,ET AL, "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20010302), vol. 276, no. 9, doi:10.1074/jbc.M009483200, ISSN 0021-9258, pages 6591 - 6604, XP002271092
OPPOSITION- Tilman Schlothauer, Sylvia Herter, Claudia Ferrara Koller, Sandra Grau-Richards, Virginie Steinhart, Christian Spick, Manfred Kubbies, Christian Klein, Pablo Umaña, Ekkehard Mössner, "Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions", PROTEIN ENGINEERING, DESIGN AND SELECTION, OXFORD JOURNAL, LONDON, GB, GB , (20161001), vol. 29, no. 10, doi:10.1093/protein/gzw040, ISSN 1741-0126, pages 457 - 466, XP055414310

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents